iShares US Pharmaceuticals ETF
101 hedge funds and large institutions have $98.4M invested in iShares US Pharmaceuticals ETF in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 13 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
12% more capital invested
Capital invested by funds: $87.9M → $98.4M (+$10.5M)
3.27% more ownership
Funds ownership: 74.23% → 77.5% (+3.3%)
0% more funds holding
Funds holding: 101 → 101 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.03M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.08M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.67M |
| 4 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$974K |
| 5 |
Morgan Stanley
New York
|
+$619K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.61M |
| 2 |
WIA
Wealthstreet Investment Advisors
Dallas,
Texas
|
-$1.08M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$457K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$426K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$358K |
IHE Hedge Fund Activity: Q2 2021 in Review
101 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2021, worth a combined $98.4M — up 12% from $87.9M a quarter earlier.
Fund positioning in IHE was balanced in Q2 2021: 13 funds opened new positions, 13 closed out, 29 added to existing stakes and 25 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $7.03M. The largest seller was Susquehanna International Group, cutting an estimated $3.61M.
- 101 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $98.4M of iShares US Pharmaceuticals ETF stock for Q2 2021, up 12% quarter-over-quarter.
- 13 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2021 and 13 closed out, a net change of 0 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2021 was Citadel Advisors, an estimated $7.03M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2021 was Susquehanna International Group, an estimated $3.61M sold.
Based on aggregated 13F filings for Q2 2021.